[Nasal septum perforation and bevacizumab].

Abstract

A 52-year-old woman, with a metastatic breast cancer, presented with a nasal septum perforation while receiving a treatment combining paclitaxel and bevacizumab. This is the fifth reported case of nasal septum perforation probably related to an anti-angiogenic therapy. A literature review and a discussion concerning the different causes of nasal septum perforation were performed.

• Authors: L Bengrine-Lefevre, P Afchain, B Chibaudel, H Gervais, C Tournigand, A De Gramont, C Louvet
• Journal: La Revue de medecine interne (Rev Med Interne) Vol. 32 Issue 4 Pg. e43-5 (Apr 2011) ISSN: 1768-3122 [Electronic] France
• Vernacular Title: Perforation de la cloison nasale et bevacizumab.
• PMID: 21470582 (Publication Type: Case Reports, English Abstract, Journal Article)
• Copyright: Copyright © 2010 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Paclitaxel

Topics

• Antibodies, Monoclonal (administration & dosage, adverse effects)
• Antibodies, Monoclonal, Humanized
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects)
• Bevacizumab
• Breast Neoplasms (complications, drug therapy, secondary)
• Female
• Humans
• Middle Aged
• Nasal Septum (drug effects, pathology)
• Nose Diseases (chemically induced, pathology)
• Paclitaxel (administration & dosage, adverse effects)